The MIE Shift: When the Model Becomes the Primary Evidence for FDA Approval
Executive Summary For a long time, the pharmaceutical industry viewed Clinical Pharmacology models as helpful supporting characters. They were tools used to guide a trial design or help justify a specific dose. As we move through 2026, a fundamental shift has taken place. The FDA and EMA have moved from Model Informed to Model Integrated […]
The MIE Shift: When the Model Becomes the Primary Evidence for FDA Approval Read More »